Actively Recruiting
OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD
Led by AstraZeneca · Updated on 2026-04-27
14308
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a retrospective, observational study, using secondary data captured in electronic health records (EHRs). The study is a part of the OPTIMISE-CKD program to assess the current CKD treatment landscape, Dapagliflozin utilisation and characterization of incident CKD patient and the burden of disease within an observation period of 39 months (August 2020-November 2024) in two cohorts (preand post-reimbursement of Dapagliflozin for CKD)
CONDITIONS
Official Title
OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have Chronic Kidney Disease defined by at least two eGFR measures 6 ml/min/1.73m2 taken 90 to 730 days apart and/or UACR 2 30 mg/g, or at least one proteinuria or CKD code measurement
- Are 18 years or older
- Have continuous enrollment in the healthcare database for 12 months before the index date
- Have continuous enrollment in the healthcare database for 12 months after the index date
You will not qualify if you...
- Have type 1 diabetes mellitus on or before the index date
- Have a diagnosis of gestational diabetes mellitus on or before the index date
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Research Site
Madrid, Spain, 28002
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here